CA2546843C - Composes et procedes pour accroitre la neurogenese - Google Patents

Composes et procedes pour accroitre la neurogenese Download PDF

Info

Publication number
CA2546843C
CA2546843C CA2546843A CA2546843A CA2546843C CA 2546843 C CA2546843 C CA 2546843C CA 2546843 A CA2546843 A CA 2546843A CA 2546843 A CA2546843 A CA 2546843A CA 2546843 C CA2546843 C CA 2546843C
Authority
CA
Canada
Prior art keywords
calcitonin
cells
receptor
ser
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2546843A
Other languages
English (en)
Other versions
CA2546843A1 (fr
Inventor
Goran Bertilsson
Rikard Erlandsson
Jonas Frisen
Anders Haegestrand
Jessica Heidrich
Nina Hellstrom
Johan Haggblad
Katarina Jansson
Jarkko Kortesmaa
Per Lindquist
Hanna Lundh
Jacqueline Mcguire
Alex Mercer
Karl Nyberg
Amina Ossoinak
Cesare Patrone
Harriet Roennholm
Lilian Wikstroem
Olof Zachrisson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Newron Sweden AB
Original Assignee
NeuroNova AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2003/005311 external-priority patent/WO2004045592A2/fr
Priority claimed from US10/850,055 external-priority patent/US6969702B2/en
Application filed by NeuroNova AB filed Critical NeuroNova AB
Priority claimed from PCT/IB2004/004451 external-priority patent/WO2005081619A2/fr
Publication of CA2546843A1 publication Critical patent/CA2546843A1/fr
Application granted granted Critical
Publication of CA2546843C publication Critical patent/CA2546843C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés visant à activer la neurogenèse par la mise en contact de tissu neuronal avec des agents modulant la neurogenèse ; et de nouvelles méthodes de traitement de troubles neurologiques utilisant des agents modulant la neurogenèse.
CA2546843A 2003-11-20 2004-11-19 Composes et procedes pour accroitre la neurogenese Expired - Fee Related CA2546843C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/IB2003/005311 WO2004045592A2 (fr) 2002-11-20 2003-11-20 Composes et methodes permettant d'augmenter la neurogenese
IBPCT/IB03/05311 2003-11-20
US10/718,071 2003-11-20
US10/718,071 US20050009847A1 (en) 2002-11-20 2003-11-20 Compounds and methods for increasing neurogenesis
US10/850,055 2004-05-19
US10/850,055 US6969702B2 (en) 2002-11-20 2004-05-19 Compounds and methods for increasing neurogenesis
PCT/IB2004/004451 WO2005081619A2 (fr) 2003-11-20 2004-11-19 Composes et procedes pour accroitre la neurogenese

Publications (2)

Publication Number Publication Date
CA2546843A1 CA2546843A1 (fr) 2005-09-09
CA2546843C true CA2546843C (fr) 2015-01-06

Family

ID=99552103

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2546843A Expired - Fee Related CA2546843C (fr) 2003-11-20 2004-11-19 Composes et procedes pour accroitre la neurogenese

Country Status (1)

Country Link
CA (1) CA2546843C (fr)

Also Published As

Publication number Publication date
CA2546843A1 (fr) 2005-09-09

Similar Documents

Publication Publication Date Title
US6969702B2 (en) Compounds and methods for increasing neurogenesis
US20090232775A1 (en) Compounds and methods for increasing neurogenesis
AU2003280117B2 (en) Compounds and methods for increasing neurogenesis
WO2005081619A2 (fr) Composes et procedes pour accroitre la neurogenese
EP1663188B1 (fr) Traitement de maladies ou de lesions du systeme nerveux avec le fty720
US20040038888A1 (en) Functional role and potential therapeutic use of PACAP, VIP and Maxadilan in relation to adult neural stem or progenitor cells
US8435949B2 (en) Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis
CA2546843C (fr) Composes et procedes pour accroitre la neurogenese
Bertilsson Compounds and methods for increasing neurogenesis
EP2741759A2 (fr) Différenciation d'oligodendrocytes
WO2006136374A2 (fr) Utilisation du gip et/ou de la vitamine d3 et d'analogues correspondants pour ameliorer la differenciation de cellules souches ou progenitrices en cellules productrices d'insuline
HK1091112B (en) Compounds and methods for increasing neurogenesis
Kim Cholecystokinin Receptor Activation Promotes Pancreatic β-Cell Survival
Vaudry et al. 7th International Symposium on VIP, PACAP and Related Peptides Rouen, France September, 11–14, 2005
US20060105958A1 (en) Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210831

MKLA Lapsed

Effective date: 20191119